YishengBio discovers, develops and commercializes biotherapeutics and vaccines using its PIKA® immunomodulating technology platform. Its commercial product, the YSJA™ alum-free lyophilized rabies vaccine, has been launched in China and provided post-exposure protection to over 16 million patients. The company reports more than 60 patents on PIKA technology across over 30 countries and regions. Its clinical pipeline includes candidates such as YS-ON-001 for advanced solid tumors, YS-HBV-001 for hepatitis B, and PIKA YS-SC2-010 for COVID-19, with other candidates in preclinical and discovery stages. YishengBio operates in China, the USA and Singapore and has over 500 employees. The company plans to expand R&D capacity, accelerate commercialization and advance multiple clinical programs, supported by recent financing to build biologics production facilities in China and Singapore.

Total raised

$130M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2021